THOR MEDICAL |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.08 NOK | +1.89% |
|
+1.31% | -16.28% |
| Feb. 28 | Transcript : Thor Medical ASA, H2 2023 Earnings Call, Feb 28, 2024 | |
| Feb. 14 | Thor Medical ASA Announces CEO Changes | CI |
Presenter SpeechAlf Bjørseth (Executives)Good morning, and welcome to this presentation of Tho...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Thor Medical ASA, formerly Nordic Nanovector ASA, is a Norway-based biopharmaceutical company. The Company is engaged in the development and commercialization of targeted therapeutics for hematological cancers. Its main product is Betalutin, a CD37-targeting radio-immunoconjugate designed to advance the treatment of non-Hodgkin lymphoma (NHL). Betalutin uses monoclonal antibodies to attack the cancer cells in two ways, first as an immunotherapy and secondly as a targeting agent for a radioactive payload and is a combination of radiation therapy and immunotherapy. The Company is also leveraging its expertise in radionuclides and CD37-targeting antibodies, along with partners, to build a pipeline of biopharmaceuticals for a range of haematological cancers.
Calendar
2024-08-29
- Q2 2024 Earnings Release
| 1st Jan change | Capi. | |
|---|---|---|
| -16.28% | 22.97M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.74B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- NANOV Stock
- News Thor Medical
- Transcript : Thor Medical ASA, H2 2023 Earnings Call, Feb 28, 2024
